NDA 209092 · Novartis
Kisqali
Ribociclib Succinate · Oral
NovelBreakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Mar 13, 2017
Approved uses
8
Original approval plus efficacy supplements
Registered trials
194
38 Phase 3, 52 recruiting
FAERS reports
32,716
27,086 serious, 4,684 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 1, 2026.
KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) 1.1 Early Breast Cancer KISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. 1.2 Advanced or Metastatic Breast Cancer KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.
Mechanism: Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and are downstream of signaling pathways which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb). In vitro , ribociclib decreased pRb phosphorylation, resulting in arrest in the G1 phase of the cell cycle and reduced proliferation in breast cancer-derived models. In vivo , treatment with single agent ribociclib in a rat xenograft model with...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 1, 2026 Supplement 27 · Efficacy · priority review LetterLabel
- Sep 17, 2024 Supplement 18 · Efficacy · priority review LetterLabelSummary Review
- Jul 22, 2024 Supplement 19 · Efficacy LetterLabel
- Oct 3, 2022 Supplement 13 · Efficacy LetterLabel
- Dec 10, 2021 Supplement 8 · Efficacy LabelLetter
- Jul 6, 2020 Supplement 5 · Efficacy LabelLetter
- Jul 18, 2018 Supplement 1 · Efficacy · priority review Breakthrough therapyLetterLabelReview
- Mar 13, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
- KISQALI · RIBOCICLIB SUCCINATE EQ 200MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ribociclib" as an intervention, any sponsor and status, largest first.
- A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03701334 · 5,101 participants · Start Dec 7, 2018 · Primary completion May 29, 2030
Drug: Ribociclib · For: Early Breast Cancer
Sites: Birmingham, Alabama; Goodyear, Arizona; Jonesboro, Arkansas · 387 sites in all
- Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT07237256 · 3,902 participants (planned) · Start Dec 18, 2025 · Primary completion Nov 30, 2033
Drug: Chemotherapy followed by endocrine therapy and ribociclib treatment · For: Breast Cancer
Sites: Amiens, France; Angers, France; Argenteuil, France · 138 sites in all
- Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02941926 · 3,246 participants · Start Nov 30, 2016 · Primary completion Nov 8, 2019
Drug: Ribociclib; Letrozole and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Chandler, Arizona; Phoenix, Arizona · 495 sites in all
- Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 InhibitorPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06996093 · 2,508 participants (planned) · Start Jun 2, 2025 · Primary completion Jun 1, 2030
Drug: 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy; aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor · For: Breast Cancer
Sites: Shanghai, China
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07391774 · 1,978 participants (planned) · Start Aug 10, 2026 · Primary completion Jul 31, 2029
Drug: Anastrozole; Chemotherapy and 3 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8 and 2 more
Sites: Jonesboro, Arkansas; Auburn, California; Berkeley, California · 264 sites in all
- Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCPivotal-lookingActive, not recruiting
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT04055493 · 1,684 participants · Start Jul 2, 2019 · Primary completion Jul 31, 2027
Drug: Ribociclib 200Mg Oral Tablet · For: Breast Cancer Female
Sites: Aalen, Germany; Baden-Baden, Germany; Böblingen, Germany · 86 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCPivotal-lookingRecruiting
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT07242352 · 1,520 participants (planned) · Start Apr 29, 2026 · Primary completion Sep 30, 2033
Drug: Elacestrant; Standard-of-care endocrine treatment · For: Breast Cancer; HR+/HER2- Breast Cancer
Sites: Mannheim, Germany; Tübingen, Germany; Esslingen am Neckar, Germany · 33 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia4,342
- fatigue3,986
- nausea3,932
- malignant neoplasm progression2,842
- death2,554
- vomiting2,210
- diarrhoea2,125
- white blood cell count decreased2,076
- pain1,940
- metastases to bone1,825
- asthenia1,680
- breast cancer metastatic1,678
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 3 |
| 2016 | 3 |
| 2017 | 507 |
| 2018 | 1,211 |
| 2019 | 2,156 |
| 2020 | 3,064 |
| 2021 | 3,676 |
| 2022 | 4,013 |
| 2023 | 5,960 |
| 2024 | 3,887 |
| 2025 | 4,574 |
| 2026 | 3,662 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kisqali (Ribociclib Succinate)
2024 spending
$775M
Beneficiaries
8,782
52,578 claims
Per beneficiary
$88,305
$296.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $128,739,776 |
| 2021 | $119,293,640 |
| 2022 | $166,342,358 |
| 2023 | $370,771,679 |
| 2024 | $775,493,707 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
Bidard FC, Mayer EL, Park YH, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Slamon D, Lipatov O, Nowecki Z, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
Hortobagyi GN, Lacko A, Sohn J, et al. · Ann Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN, Stemmer SM, Burris HA, et al. · Ann Oncol 2018 · Clinical Trial, Phase III, Multicenter Study
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.